Literature DB >> 18470760

Testing for positive control activity in a thorough QTc study.

Joanne Zhang1.   

Abstract

The ICH E14 guidance (ICH, 2005) recommend that a concurrent positive control should be included in a thorough QTc clinical trial to validate the study. The ICH E14 guidance (ICH, 2005) state that "The positive control should have an effect on the mean QTc interval of about 5 ms (i.e., an effect that is close to the QTc effect that represents the threshold of regulatory concern, around 5 ms)". This task may be carried out through some statistical tests. The current practice is to test at each time point where QT measurements are collected. This method is usually not efficient. In this article, I discuss two types of statistical procedures. The first one is a local statistical test to make a time-point-specific claim, i.e., to claim a mild QTc effect due to the positive control at some specific time points. A different approach, named as a global test, is also proposed, to make a general claim that the mean difference of the positive control and placebo after baseline adjustment will be about 5 ms without specifying at which time points. An example will be used to illustrate how to apply the two procedures. How to best allocate sample size in a parallel QTc study is also discussed in this paper.

Entities:  

Mesh:

Year:  2008        PMID: 18470760     DOI: 10.1080/10543400801995478

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  12 in total

Review 1.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

2.  Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect.

Authors:  Karin Meiser; Pierre Jordaan; Sasha Latypova; Borje Darpo
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-12-19       Impact factor: 1.468

3.  Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.

Authors:  Cynthia L Green; Paul Kligfield; Samuel George; Ihor Gussak; Branislav Vajdic; Philip Sager; Mitchell W Krucoff
Journal:  Am Heart J       Date:  2012-02-27       Impact factor: 4.749

Review 4.  Early QT assessment--how can our confidence in the data be improved?

Authors:  Borje Darpo; Christine Garnett
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 5.  Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 6.  Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?

Authors:  Norman Stockbridge; Joel Morganroth; Rashmi R Shah; Christine Garnett
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

7.  Baseline correction in parallel thorough QT studies.

Authors:  Joanne Zhang; Qianyu Dang; Marek Malik
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

8.  Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

Authors:  Corina Loghin; Harry Haber; Charles M Beasley; Prajakti A Kothare; Lynnette Kauffman; John April; Ling Jin; Albert J Allen; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 9.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

10.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.